

Rec'd 5/25/04  
16

March 1, 2004 (3pm)

Conference Call regarding Glucosamine and Chondroitin Sulfate and Osteoarthritis health claim petition submitted by Emord and Associates on behalf of Weider Nutrition International, Inc. – Docket No. 2004P-0059

FDA attendance:

- Laura Tarantino, PhD, Acting Director, Office of Nutritional products and Labeling and Dietary Supplements
- Kathy Ellwood, PhD, Director, Nutrition Products and Labeling Staff
- Louisa Nickerson, J.D., Office of Chief Counsel
- Gloria Overholzer, J.D., Office of Chief Counsel

Emord and Associates, Ltd. attendance:

- Claudia Lewis-Eng, J.D.

Meeting Minutes:

- FDA explained the need for a food advisory committee meeting and that all pertinent information will be given as soon as it is reasonable to do so.
- The scientific experts associated with the petitioner are allowed to attend and present at the advisory committee meeting.
- After the advisory committee meeting, FDA will have all the information they need to make a decision.
- A decision for the first 3 claims pertaining to “reducing the risk of OA” will be decided 60 days after the advisory committee meeting.
- A decision for the last 6 claims pertaining to “reducing the risk of joint degeneration and cartilage deterioration” will be decided 90 days after the advisory committee meeting, in case consumer studies are necessary.
- Claudia Lewis-Eng stated that she will talk with her client and get back to FDA.

Kathy Ellwood, PhD  
3/3/2004

2004P-0059

MT 1